Trial Profile
Investigation of pathways regulating cell survival and early antiangiogenic response to single agent Everolimus or Rapamycin in renal cancer.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 18 Jun 2019
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sirolimus (Primary)
- Indications Renal cancer
- Focus Pharmacodynamics
- 17 Jun 2019 Status changed from recruiting to discontinued.
- 17 Jun 2019 According to European Clinical Trials Database record, this trial is Prematurely ended (End date: 04 Oct 2012).
- 25 Feb 2012 Planned end date changed from 22 Sep 2013 to 22 Mar 2015 as reported by EudraCT.